Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure ...
January 29, 2025 08:45 ET | Source: Palisade Bio, Inc.

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
January 22, 2025 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29th at 2:20 PM ET Carlsbad, CA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a...
January 16, 2025 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of...
January 03, 2025 17:20 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
December 17, 2024 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
December 13, 2024 16:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
December 12, 2024 12:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
December 03, 2024 08:15 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,”...
November 21, 2024 08:15 ET | Source: Palisade Bio, Inc.

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic...